首页 > 最新文献

Research Synthesis Methods最新文献

英文 中文
Individual participant data meta-analysis to examine linear or non-linear treatment-covariate interactions at multiple time-points for a continuous outcome 对个人参与者数据进行荟萃分析,以检查连续结果在多个时间点上的线性或非线性治疗-共变因素交互作用
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-16 DOI: 10.1002/jrsm.1750
Miriam Hattle, Joie Ensor, Katie Scandrett, Marienke van Middelkoop, Danielle A. van der Windt, Melanie A. Holden, Richard D. Riley

Individual participant data (IPD) meta-analysis projects obtain, harmonise, and synthesise original data from multiple studies. Many IPD meta-analyses of randomised trials are initiated to identify treatment effect modifiers at the individual level, thus requiring statistical modelling of interactions between treatment effect and participant-level covariates. Using a two-stage approach, the interaction is estimated in each trial separately and combined in a meta-analysis. In practice, two complications often arise with continuous outcomes: examining non-linear relationships for continuous covariates and dealing with multiple time-points. We propose a two-stage multivariate IPD meta-analysis approach that summarises non-linear treatment-covariate interaction functions at multiple time-points for continuous outcomes. A set-up phase is required to identify a small set of time-points; relevant knot positions for a spline function, at identical locations in each trial; and a common reference group for each covariate. Crucially, the multivariate approach can include participants or trials with missing outcomes at some time-points. In the first stage, restricted cubic spline functions are fitted and their interaction with each discrete time-point is estimated in each trial separately. In the second stage, the parameter estimates defining these multiple interaction functions are jointly synthesised in a multivariate random-effects meta-analysis model accounting for within-trial and across-trial correlation. These meta-analysis estimates define the summary non-linear interactions at each time-point, which can be displayed graphically alongside confidence intervals. The approach is illustrated using an IPD meta-analysis examining effect modifiers for exercise interventions in osteoarthritis, which shows evidence of non-linear relationships and small gains in precision by analysing all time-points jointly.

个体参与者数据(IPD)荟萃分析项目从多项研究中获取、协调和综合原始数据。许多随机试验的 IPD 元分析都是为了确定个体水平的治疗效果调节因素,因此需要对治疗效果与参与者水平协变量之间的交互作用进行统计建模。采用两阶段方法,分别对每项试验的交互作用进行估计,并在荟萃分析中进行合并。在实践中,连续性结果往往会出现两种复杂情况:检查连续性协变量的非线性关系和处理多个时间点。我们提出了一种两阶段多变量 IPD 荟萃分析方法,可总结连续性结果在多个时间点的非线性治疗-协变量交互作用函数。需要一个设置阶段来确定一小组时间点;在每个试验的相同位置确定样条函数的相关结点位置;以及为每个协变量确定一个共同的参照组。最重要的是,多变量方法可以包括在某些时间点结果缺失的参与者或试验。在第一阶段,对限制性三次样条函数进行拟合,并在每个试验中分别估计其与每个离散时间点的交互作用。在第二阶段,定义这些多重交互作用函数的参数估算值将在多元随机效应荟萃分析模型中联合合成,并考虑试验内和试验间的相关性。这些荟萃分析估计值定义了每个时间点的非线性交互作用概要,可与置信区间一起以图形方式显示。该方法使用 IPD 元分析对骨关节炎运动干预的效应修饰因子进行了研究,结果显示了非线性关系的证据,并且通过联合分析所有时间点,精度略有提高。
{"title":"Individual participant data meta-analysis to examine linear or non-linear treatment-covariate interactions at multiple time-points for a continuous outcome","authors":"Miriam Hattle,&nbsp;Joie Ensor,&nbsp;Katie Scandrett,&nbsp;Marienke van Middelkoop,&nbsp;Danielle A. van der Windt,&nbsp;Melanie A. Holden,&nbsp;Richard D. Riley","doi":"10.1002/jrsm.1750","DOIUrl":"10.1002/jrsm.1750","url":null,"abstract":"<p>Individual participant data (IPD) meta-analysis projects obtain, harmonise, and synthesise original data from multiple studies. Many IPD meta-analyses of randomised trials are initiated to identify treatment effect modifiers at the individual level, thus requiring statistical modelling of interactions between treatment effect and participant-level covariates. Using a two-stage approach, the interaction is estimated in each trial separately and combined in a meta-analysis. In practice, two complications often arise with continuous outcomes: examining non-linear relationships for continuous covariates and dealing with multiple time-points. We propose a two-stage multivariate IPD meta-analysis approach that summarises non-linear treatment-covariate interaction functions at multiple time-points for continuous outcomes. A set-up phase is required to identify a small set of time-points; relevant knot positions for a spline function, at identical locations in each trial; and a common reference group for each covariate. Crucially, the multivariate approach can include participants or trials with missing outcomes at some time-points. In the first stage, restricted cubic spline functions are fitted and their interaction with each discrete time-point is estimated in each trial separately. In the second stage, the parameter estimates defining these multiple interaction functions are jointly synthesised in a multivariate random-effects meta-analysis model accounting for within-trial and across-trial correlation. These meta-analysis estimates define the summary non-linear interactions at each time-point, which can be displayed graphically alongside confidence intervals. The approach is illustrated using an IPD meta-analysis examining effect modifiers for exercise interventions in osteoarthritis, which shows evidence of non-linear relationships and small gains in precision by analysing all time-points jointly.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1001-1016"},"PeriodicalIF":5.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data sharing policies across health research globally: Cross-sectional meta-research study 全球健康研究数据共享政策:横断面荟萃研究
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-14 DOI: 10.1002/jrsm.1757
Aidan C. Tan, Angela C. Webster, Sol Libesman, Zijing Yang, Rani R. Chand, Weber Liu, Talia Palacios, Kylie E. Hunter, Anna Lene Seidler

Background

Data sharing improves the value, synthesis, and integrity of research, but rates are low. Data sharing might be improved if data sharing policies were prominent and actionable at every stage of research. We aimed to systematically describe the epidemiology of data sharing policies across the health research lifecycle.

Methods

This was a cross-sectional analysis of the data sharing policies of the largest health research funders, all national ethics committees, all clinical trial registries, the highest-impact medical journals, and all medical research data repositories. Stakeholders' official websites, online reports, and other records were reviewed up to May 2022. The strength and characteristics of their data sharing policies were assessed, including their policies on data sharing intention statements (a.k.a. data accessibility statements) and on data sharing specifically for coronavirus disease studies. Data were manually extracted in duplicate, and policies were descriptively analysed by their stakeholder and characteristics.

Results

Nine hundred and thirty-five eligible stakeholders were identified: 110 funders, 124 ethics committees, 18 trial registries, 273 journals, and 410 data repositories. Data sharing was required by 41% (45/110) of funders, no ethics committees or trial registries, 19% (52/273) of journals and 6% (24/410) of data repositories. Among funder types, a higher proportion of private (63%, 35/55) and philanthropic (67%, 4/6) funders required data sharing than public funders (12%, 6/49).

Conclusion

Data sharing requirements, and even recommendations, were insufficient across health research. Where data sharing was required or recommended, there was limited guidance on implementation. We describe multiple pathways to improve the implementation of data sharing. Public funders and ethics committees are two stakeholders with particularly important untapped opportunities.

背景数据共享提高了研究的价值、综合性和完整性,但数据共享率却很低。如果数据共享政策在研究的每个阶段都非常突出且具有可操作性,那么数据共享的情况可能会得到改善。我们的目的是系统地描述整个健康研究生命周期中数据共享政策的流行病学。方法这是对最大的健康研究资助机构、所有国家伦理委员会、所有临床试验注册机构、影响力最大的医学期刊以及所有医学研究数据存储库的数据共享政策进行的横断面分析。对利益相关者截至 2022 年 5 月的官方网站、在线报告和其他记录进行了审查。对其数据共享政策的力度和特点进行了评估,包括其数据共享意向声明(又称数据可访问性声明)和专门针对冠状病毒疾病研究的数据共享政策。人工提取的数据一式两份,并按照利益相关者和特征对政策进行了描述性分析:结果确定了 935 个符合条件的利益相关者:110 个资助者、124 个伦理委员会、18 个试验登记处、273 个期刊和 410 个数据存储库。41%的资助者(45/110)、无伦理委员会或试验登记处、19%的期刊(52/273)和6%的数据存储库(24/410)要求数据共享。在资助者类型中,要求数据共享的私人资助者(63%,35/55)和慈善资助者(67%,4/6)的比例高于公共资助者(12%,6/49)。在有数据共享要求或建议的地方,实施指导也很有限。我们介绍了改善数据共享实施的多种途径。公共资助者和伦理委员会是两个利益相关者,它们拥有尚未开发的重要机会。
{"title":"Data sharing policies across health research globally: Cross-sectional meta-research study","authors":"Aidan C. Tan,&nbsp;Angela C. Webster,&nbsp;Sol Libesman,&nbsp;Zijing Yang,&nbsp;Rani R. Chand,&nbsp;Weber Liu,&nbsp;Talia Palacios,&nbsp;Kylie E. Hunter,&nbsp;Anna Lene Seidler","doi":"10.1002/jrsm.1757","DOIUrl":"10.1002/jrsm.1757","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Data sharing improves the value, synthesis, and integrity of research, but rates are low. Data sharing might be improved if data sharing policies were prominent and actionable at every stage of research. We aimed to systematically describe the epidemiology of data sharing policies across the health research lifecycle.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a cross-sectional analysis of the data sharing policies of the largest health research funders, all national ethics committees, all clinical trial registries, the highest-impact medical journals, and all medical research data repositories. Stakeholders' official websites, online reports, and other records were reviewed up to May 2022. The strength and characteristics of their data sharing policies were assessed, including their policies on data sharing intention statements (a.k.a. data accessibility statements) and on data sharing specifically for coronavirus disease studies. Data were manually extracted in duplicate, and policies were descriptively analysed by their stakeholder and characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nine hundred and thirty-five eligible stakeholders were identified: 110 funders, 124 ethics committees, 18 trial registries, 273 journals, and 410 data repositories. Data sharing was required by 41% (45/110) of funders, no ethics committees or trial registries, 19% (52/273) of journals and 6% (24/410) of data repositories. Among funder types, a higher proportion of private (63%, 35/55) and philanthropic (67%, 4/6) funders required data sharing than public funders (12%, 6/49).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Data sharing requirements, and even recommendations, were insufficient across health research. Where data sharing was required or recommended, there was limited guidance on implementation. We describe multiple pathways to improve the implementation of data sharing. Public funders and ethics committees are two stakeholders with particularly important untapped opportunities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1060-1071"},"PeriodicalIF":5.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1757","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of use of the revised Cochrane Risk of Bias tool (RoB 2) in Cochrane and non-Cochrane systematic reviews published in 2023 and 2024 2023 年和 2024 年发表的科克伦和非科克伦系统综述中使用修订版科克伦偏倚风险工具(RoB 2)的频率
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-10 DOI: 10.1002/jrsm.1755
Alejandro Sandoval-Lentisco, José A. López-López, Julio Sánchez-Meca
{"title":"Frequency of use of the revised Cochrane Risk of Bias tool (RoB 2) in Cochrane and non-Cochrane systematic reviews published in 2023 and 2024","authors":"Alejandro Sandoval-Lentisco,&nbsp;José A. López-López,&nbsp;Julio Sánchez-Meca","doi":"10.1002/jrsm.1755","DOIUrl":"10.1002/jrsm.1755","url":null,"abstract":"","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1244-1245"},"PeriodicalIF":5.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A discrete time-to-event model for the meta-analysis of full ROC curves 用于全 ROC 曲线荟萃分析的离散时间到事件模型。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-06 DOI: 10.1002/jrsm.1753
Ferdinand Valentin Stoye, Claudia Tschammler, Oliver Kuss, Annika Hoyer

The development of new statistical models for the meta-analysis of diagnostic test accuracy studies is still an ongoing field of research, especially with respect to summary receiver operating characteristic (ROC) curves. In the recently published updated version of the “Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy”, the authors point to the challenges of this kind of meta-analysis and propose two approaches. However, both of them come with some disadvantages, such as the nonstraightforward choice of priors in Bayesian models or the requirement of a two-step approach where parameters are estimated for the individual studies, followed by summarizing the results. As an alternative, we propose a novel model by applying methods from time-to-event analysis. To this task we use the discrete proportional hazard approach to treat the different diagnostic thresholds, that provide means to estimate sensitivity and specificity and are reported by the single studies, as categorical variables in a generalized linear mixed model, using both the logit- and the asymmetric cloglog-link. This leads to a model specification with threshold-specific discrete hazards, avoiding a linear dependency between thresholds, discrete hazard, and sensitivity/specificity and thus increasing model flexibility. We compare the resulting models to approaches from the literature in a simulation study. While the estimated area under the summary ROC curve is estimated comparably well in most approaches, the results depict substantial differences in the estimated sensitivities and specificities. We also show the practical applicability of the models to data from a meta-analysis for the screening of type 2 diabetes.

为诊断测试准确性研究的荟萃分析开发新的统计模型仍是一个持续的研究领域,尤其是在接收者操作特征曲线(ROC)汇总方面。在最近出版的《Cochrane 诊断测试准确性系统综述手册》更新版中,作者指出了此类荟萃分析所面临的挑战,并提出了两种方法。然而,这两种方法都有一些缺点,比如贝叶斯模型中先验值的选择并不简单,或者需要分两步进行,即先估计单个研究的参数,然后再总结结果。作为一种替代方法,我们提出了一种应用时间到事件分析方法的新型模型。为此,我们采用了离散比例危险法,将不同的诊断阈值作为分类变量,在广义线性混合模型中使用 logit 和非对称 cloglog 链接来处理,这些阈值提供了估算敏感性和特异性的方法,并由单项研究报告。这导致了一种具有阈值特异性离散危害的模型规范,避免了阈值、离散危害和灵敏度/特异性之间的线性依赖关系,从而提高了模型的灵活性。在模拟研究中,我们将得出的模型与文献中的方法进行了比较。虽然大多数方法都能很好地估算出 ROC 曲线下的估计面积,但结果表明在估计灵敏度和特异性方面存在很大差异。我们还展示了这些模型在 2 型糖尿病筛查荟萃分析数据中的实际应用性。
{"title":"A discrete time-to-event model for the meta-analysis of full ROC curves","authors":"Ferdinand Valentin Stoye,&nbsp;Claudia Tschammler,&nbsp;Oliver Kuss,&nbsp;Annika Hoyer","doi":"10.1002/jrsm.1753","DOIUrl":"10.1002/jrsm.1753","url":null,"abstract":"<p>The development of new statistical models for the meta-analysis of diagnostic test accuracy studies is still an ongoing field of research, especially with respect to summary receiver operating characteristic (ROC) curves. In the recently published updated version of the “<i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i>”, the authors point to the challenges of this kind of meta-analysis and propose two approaches. However, both of them come with some disadvantages, such as the nonstraightforward choice of priors in Bayesian models or the requirement of a two-step approach where parameters are estimated for the individual studies, followed by summarizing the results. As an alternative, we propose a novel model by applying methods from time-to-event analysis. To this task we use the discrete proportional hazard approach to treat the different diagnostic thresholds, that provide means to estimate sensitivity and specificity and are reported by the single studies, as categorical variables in a generalized linear mixed model, using both the logit- and the asymmetric cloglog-link. This leads to a model specification with threshold-specific discrete hazards, avoiding a linear dependency between thresholds, discrete hazard, and sensitivity/specificity and thus increasing model flexibility. We compare the resulting models to approaches from the literature in a simulation study. While the estimated area under the summary ROC curve is estimated comparably well in most approaches, the results depict substantial differences in the estimated sensitivities and specificities. We also show the practical applicability of the models to data from a meta-analysis for the screening of type 2 diabetes.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1031-1048"},"PeriodicalIF":5.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fast-and-frugal decision tree for the rapid critical appraisal of systematic reviews 用于快速批判性评估系统综述的 "快速节俭决策树"。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-05 DOI: 10.1002/jrsm.1754
Robert C. Lorenz, Mirjam Jenny, Anja Jacobs, Katja Matthias

Conducting high-quality overviews of reviews (OoR) is time-consuming. Because the quality of systematic reviews (SRs) varies, it is necessary to critically appraise SRs when conducting an OoR. A well-established appraisal tool is A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, which takes about 15–32 min per application. To save time, we developed two fast-and-frugal decision trees (FFTs) for assessing the methodological quality of SR for OoR either during the full-text screening stage (Screening FFT) or to the resulting pool of SRs (Rapid Appraisal FFT). To build a data set for developing the FFT, we identified published AMSTAR 2 appraisals. Overall confidence ratings of the AMSTAR 2 were used as a criterion and the 16 items as cues. One thousand five hundred and nineteen appraisals were obtained from 24 publications and divided into training and test data sets. The resulting Screening FFT consists of three items and correctly identifies all non-critically low-quality SRs (sensitivity of 100%), but has a positive predictive value of 59%. The three-item Rapid Appraisal FFT correctly identifies 80% of the high-quality SRs and correctly identifies 97% of the low-quality SRs, resulting in an accuracy of 95%. The FFTs require about 10% of the 16 AMSTAR 2 items. The Screening FFT may be applied during full-text screening to exclude SRs with critically low quality. The Rapid Appraisal FFT may be applied to the final SR pool to identify SR that might be of high methodological quality.

进行高质量的综述(OoR)非常耗时。由于系统性综述(SR)的质量参差不齐,因此在进行 OoR 时有必要对系统性综述进行严格评估。一个成熟的评估工具是系统综述评估工具(AMSTAR)2,每次应用大约需要 15-32 分钟。为了节省时间,我们开发了两种快速、节俭的决策树(FFT),用于在全文筛选阶段(筛选 FFT)或由此产生的系统综述库(快速评估 FFT)中评估 OoR 的系统综述方法学质量。为了建立开发 FFT 的数据集,我们确定了已发表的 AMSTAR 2 评估。以 AMSTAR 2 的总体信心评级为标准,以 16 个项目为线索。我们从 24 份出版物中获得了 1519 份鉴定,并将其分为训练数据集和测试数据集。由此产生的筛选快速鉴定模型由三个项目组成,能正确识别所有非临界低质量 SR(灵敏度为 100%),但阳性预测值为 59%。由三个项目组成的快速评估 FFT 能正确识别 80% 的高质量 SR,正确识别 97% 的低质量 SR,准确率达到 95%。FFT需要16个AMSTAR 2项目中的大约10%。筛选 FFT 可用于全文筛选,以排除质量极低的 SR。快速评估 FFT 可用于最终 SR 库,以确定可能具有较高方法学质量的 SR。
{"title":"Fast-and-frugal decision tree for the rapid critical appraisal of systematic reviews","authors":"Robert C. Lorenz,&nbsp;Mirjam Jenny,&nbsp;Anja Jacobs,&nbsp;Katja Matthias","doi":"10.1002/jrsm.1754","DOIUrl":"10.1002/jrsm.1754","url":null,"abstract":"<p>Conducting high-quality overviews of reviews (OoR) is time-consuming. Because the quality of systematic reviews (SRs) varies, it is necessary to critically appraise SRs when conducting an OoR. A well-established appraisal tool is A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, which takes about 15–32 min per application. To save time, we developed two fast-and-frugal decision trees (FFTs) for assessing the methodological quality of SR for OoR either during the full-text screening stage (Screening FFT) or to the resulting pool of SRs (Rapid Appraisal FFT). To build a data set for developing the FFT, we identified published AMSTAR 2 appraisals. Overall confidence ratings of the AMSTAR 2 were used as a criterion and the 16 items as cues. One thousand five hundred and nineteen appraisals were obtained from 24 publications and divided into training and test data sets. The resulting Screening FFT consists of three items and correctly identifies all non-critically low-quality SRs (sensitivity of 100%), but has a positive predictive value of 59%. The three-item Rapid Appraisal FFT correctly identifies 80% of the high-quality SRs and correctly identifies 97% of the low-quality SRs, resulting in an accuracy of 95%. The FFTs require about 10% of the 16 AMSTAR 2 items. The Screening FFT may be applied during full-text screening to exclude SRs with critically low quality. The Rapid Appraisal FFT may be applied to the final SR pool to identify SR that might be of high methodological quality.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1049-1059"},"PeriodicalIF":5.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1754","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Narrative reanalysis: A methodological framework for a new brand of reviews 叙事再分析:新品牌评论的方法框架。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-09-04 DOI: 10.1002/jrsm.1751
Steven Hall, Erin Leeder

In response to the evolving needs of knowledge synthesis, this manuscript introduces the concept of narrative reanalysis, a method that refines data from initial reviews, such as systematic and reviews, to focus on specific sub-phenomena. Unlike traditional narrative reviews, which lack the methodological rigor of systematic reviews and are broader in scope, our methodological framework for narrative reanalysis applies a structured, systematic framework to the interpretation of existing data. This approach enables a focused investigation of nuanced topics within a broader dataset, enhancing understanding and generating new insights. We detail a five-stage methodological framework that guides the narrative reanalysis process: (1) retrieval of an initial review, (2) identification and justification of a sub-phenomenon, (3) expanded search, selection, and extraction of data, (4) reanalyzing the sub-phenomenon, and (5) writing the report. The proposed framework aims to standardize narrative reanalysis, advocating for its use in academic and research settings to foster more rigorous and insightful literature reviews. This approach bridges the methodological gap between narrative and systematic reviews, offering a valuable tool for researchers to explore detailed aspects of broader topics without the extensive resources required for systematic reviews.

为了满足不断发展的知识综合需求,本手稿引入了叙事再分析的概念,这是一种对系统性综述和综述等初始综述的数据进行提炼的方法,重点关注特定的子现象。传统的叙事性综述缺乏系统性综述的方法论严谨性,而且范围较广,与之不同的是,我们的叙事性再分析方法框架采用了结构化、系统化的框架来解释现有数据。这种方法能够在更广泛的数据集中对细微的主题进行重点调查,从而加深理解并产生新的见解。我们详细介绍了指导叙事再分析过程的五阶段方法框架:(1)检索初步综述,(2)识别和论证子现象,(3)扩展搜索、选择和提取数据,(4)重新分析子现象,以及(5)撰写报告。建议的框架旨在规范叙事性再分析,倡导在学术和研究环境中使用这种方法,以促进更严谨、更有洞察力的文献综述。这种方法弥补了叙事性综述与系统性综述之间在方法论上的差距,为研究人员提供了一种宝贵的工具,使他们能够在不需要系统性综述所需的大量资源的情况下,探索更广泛主题的细节方面。
{"title":"Narrative reanalysis: A methodological framework for a new brand of reviews","authors":"Steven Hall,&nbsp;Erin Leeder","doi":"10.1002/jrsm.1751","DOIUrl":"10.1002/jrsm.1751","url":null,"abstract":"<p>In response to the evolving needs of knowledge synthesis, this manuscript introduces the concept of narrative reanalysis, a method that refines data from initial reviews, such as systematic and reviews, to focus on specific sub-phenomena. Unlike traditional narrative reviews, which lack the methodological rigor of systematic reviews and are broader in scope, our methodological framework for narrative reanalysis applies a structured, systematic framework to the interpretation of existing data. This approach enables a focused investigation of nuanced topics within a broader dataset, enhancing understanding and generating new insights. We detail a five-stage methodological framework that guides the narrative reanalysis process: (1) retrieval of an initial review, (2) identification and justification of a sub-phenomenon, (3) expanded search, selection, and extraction of data, (4) reanalyzing the sub-phenomenon, and (5) writing the report. The proposed framework aims to standardize narrative reanalysis, advocating for its use in academic and research settings to foster more rigorous and insightful literature reviews. This approach bridges the methodological gap between narrative and systematic reviews, offering a valuable tool for researchers to explore detailed aspects of broader topics without the extensive resources required for systematic reviews.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"1017-1030"},"PeriodicalIF":5.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zero- and few-shot prompting of generative large language models provides weak assessment of risk of bias in clinical trials 生成式大语言模型的零次和少量提示可对临床试验中的偏差风险进行微弱评估。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-08-23 DOI: 10.1002/jrsm.1749
Simon Šuster, Timothy Baldwin, Karin Verspoor

Existing systems for automating the assessment of risk-of-bias (RoB) in medical studies are supervised approaches that require substantial training data to work well. However, recent revisions to RoB guidelines have resulted in a scarcity of available training data. In this study, we investigate the effectiveness of generative large language models (LLMs) for assessing RoB. Their application requires little or no training data and, if successful, could serve as a valuable tool to assist human experts during the construction of systematic reviews. Following Cochrane's latest guidelines (RoB2) designed for human reviewers, we prepare instructions that are fed as input to LLMs, which then infer the risk associated with a trial publication. We distinguish between two modelling tasks: directly predicting RoB2 from text; and employing decomposition, in which a RoB2 decision is made after the LLM responds to a series of signalling questions. We curate new testing data sets and evaluate the performance of four general- and medical-domain LLMs. The results fall short of expectations, with LLMs seldom surpassing trivial baselines. On the direct RoB2 prediction test set (n = 5993), LLMs perform akin to the baselines (F1: 0.1–0.2). In the decomposition task setup (n = 28,150), similar F1 scores are observed. Our additional comparative evaluation on RoB1 data also reveals results substantially below those of a supervised system. This testifies to the difficulty of solving this task based on (complex) instructions alone. Using LLMs as an assisting technology for assessing RoB2 thus currently seems beyond their reach.

现有的医学研究偏倚风险(RoB)自动评估系统是一种监督式方法,需要大量的训练数据才能正常工作。然而,最近对 RoB 指南的修订导致可用训练数据的匮乏。在本研究中,我们研究了生成式大型语言模型(LLM)在评估 RoB 方面的有效性。它们的应用只需要很少或不需要训练数据,如果成功的话,可以作为一种有价值的工具,在构建系统综述的过程中为人类专家提供帮助。根据科克伦为人类审稿人设计的最新指南(RoB2),我们准备了一些说明,作为 LLM 的输入,然后由 LLM 推断与试验出版物相关的风险。我们区分了两种建模任务:从文本中直接预测 RoB2;以及采用分解法,在 LLM 回答一系列信号问题后做出 RoB2 决定。我们策划了新的测试数据集,并评估了四种通用和医疗领域 LLM 的性能。结果没有达到预期,LLM 很少超过微不足道的基线。在直接的 RoB2 预测测试集(n = 5993)上,LLM 的表现与基线相似(F1:0.1-0.2)。在分解任务设置(n = 28,150)中,也观察到了类似的 F1 分数。我们在 RoB1 数据上进行的额外比较评估也显示,结果大大低于监督系统。这证明了仅凭(复杂的)指令来解决这一任务的难度。因此,使用 LLM 作为评估 RoB2 的辅助技术目前似乎还力不从心。
{"title":"Zero- and few-shot prompting of generative large language models provides weak assessment of risk of bias in clinical trials","authors":"Simon Šuster,&nbsp;Timothy Baldwin,&nbsp;Karin Verspoor","doi":"10.1002/jrsm.1749","DOIUrl":"10.1002/jrsm.1749","url":null,"abstract":"<p>Existing systems for automating the assessment of risk-of-bias (RoB) in medical studies are supervised approaches that require substantial training data to work well. However, recent revisions to RoB guidelines have resulted in a scarcity of available training data. In this study, we investigate the effectiveness of generative large language models (LLMs) for assessing RoB. Their application requires little or no training data and, if successful, could serve as a valuable tool to assist human experts during the construction of systematic reviews. Following Cochrane's latest guidelines (RoB2) designed for human reviewers, we prepare instructions that are fed as input to LLMs, which then infer the risk associated with a trial publication. We distinguish between two modelling tasks: directly predicting RoB2 from text; and employing decomposition, in which a RoB2 decision is made after the LLM responds to a series of signalling questions. We curate new testing data sets and evaluate the performance of four general- and medical-domain LLMs. The results fall short of expectations, with LLMs seldom surpassing trivial baselines. On the direct RoB2 prediction test set (<i>n</i> = 5993), LLMs perform akin to the baselines (F1: 0.1–0.2). In the decomposition task setup (<i>n</i> = 28,150), similar F1 scores are observed. Our additional comparative evaluation on RoB1 data also reveals results substantially below those of a supervised system. This testifies to the difficulty of solving this task based on (complex) instructions alone. Using LLMs as an assisting technology for assessing RoB2 thus currently seems beyond their reach.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"988-1000"},"PeriodicalIF":5.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1749","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142034719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of the individual participant data integrity tool for assessing the integrity of randomised trials using individual participant data 开发个人参与者数据完整性工具,用于利用个人参与者数据评估随机试验的完整性。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-08-18 DOI: 10.1002/jrsm.1739
Kylie E. Hunter, Mason Aberoumand, Sol Libesman, James X. Sotiropoulos, Jonathan G. Williams, Wentao Li, Jannik Aagerup, Ben W. Mol, Rui Wang, Angie Barba, Nipun Shrestha, Angela C. Webster, Anna Lene Seidler

Increasing integrity concerns in medical research have prompted the development of tools to detect untrustworthy studies. Existing tools primarily assess published aggregate data (AD), though scrutiny of individual participant data (IPD) is often required to detect trustworthiness issues. Thus, we developed the IPD Integrity Tool for detecting integrity issues in randomised trials with IPD available. This manuscript describes the development of this tool. We conducted a literature review to collate and map existing integrity items. These were discussed with an expert advisory group; agreed items were included in a standardised tool and automated where possible. We piloted this tool in two IPD meta-analyses (including 116 trials) and conducted preliminary validation checks on 13 datasets with and without known integrity issues. We identified 120 integrity items: 54 could be conducted using AD, 48 required IPD, and 18 were possible with AD, but more comprehensive with IPD. An initial reduced tool was developed through consensus involving 13 advisors, featuring 11 AD items across four domains, and 12 IPD items across eight domains. The tool was iteratively refined throughout piloting and validation. All studies with known integrity issues were accurately identified during validation. The final tool includes seven AD domains with 13 items and eight IPD domains with 18 items. The quality of evidence informing healthcare relies on trustworthy data. We describe the development of a tool to enable researchers, editors, and others to detect integrity issues using IPD. Detailed instructions for its application are published as a complementary manuscript in this issue.

医学研究中对诚信的关注与日俱增,这促使人们开发各种工具来检测不可信的研究。现有的工具主要评估已发表的总体数据(AD),但要检测可信度问题,往往需要对个体参与者数据(IPD)进行仔细检查。因此,我们开发了IPD完整性工具,用于检测有IPD的随机试验中的完整性问题。本手稿介绍了这一工具的开发过程。我们进行了文献综述,整理并绘制了现有的诚信项目。我们与专家顾问小组讨论了这些项目;达成一致的项目被纳入标准化工具,并在可能的情况下实现了自动化。我们在两项 IPD 元分析(包括 116 项试验)中试用了这一工具,并对存在和不存在已知完整性问题的 13 个数据集进行了初步验证检查。我们确定了 120 个完整性项目:其中 54 项可以使用 AD 分析,48 项需要 IPD 分析,18 项可以使用 AD 分析,但 IPD 分析更为全面。在 13 位顾问的共同努力下,我们开发出了一个初步缩减工具,其中 11 个 AD 项目横跨 4 个领域,12 个 IPD 项目横跨 8 个领域。该工具在试用和验证过程中不断改进。在验证过程中,准确识别了所有存在已知完整性问题的研究。最终工具包括 7 个 AD 领域 13 个项目和 8 个 IPD 领域 18 个项目。为医疗保健提供依据的证据质量依赖于可信的数据。我们介绍了该工具的开发过程,该工具可帮助研究人员、编辑及其他人员利用 IPD 检测诚信问题。详细的应用说明将作为本期的补充手稿发表。
{"title":"Development of the individual participant data integrity tool for assessing the integrity of randomised trials using individual participant data","authors":"Kylie E. Hunter,&nbsp;Mason Aberoumand,&nbsp;Sol Libesman,&nbsp;James X. Sotiropoulos,&nbsp;Jonathan G. Williams,&nbsp;Wentao Li,&nbsp;Jannik Aagerup,&nbsp;Ben W. Mol,&nbsp;Rui Wang,&nbsp;Angie Barba,&nbsp;Nipun Shrestha,&nbsp;Angela C. Webster,&nbsp;Anna Lene Seidler","doi":"10.1002/jrsm.1739","DOIUrl":"10.1002/jrsm.1739","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Increasing integrity concerns in medical research have prompted the development of tools to detect untrustworthy studies. Existing tools primarily assess published aggregate data (AD), though scrutiny of individual participant data (IPD) is often required to detect trustworthiness issues. Thus, we developed the IPD Integrity Tool for detecting integrity issues in randomised trials with IPD available. This manuscript describes the development of this tool. We conducted a literature review to collate and map existing integrity items. These were discussed with an expert advisory group; agreed items were included in a standardised tool and automated where possible. We piloted this tool in two IPD meta-analyses (including 116 trials) and conducted preliminary validation checks on 13 datasets with and without known integrity issues. We identified 120 integrity items: 54 could be conducted using AD, 48 required IPD, and 18 were possible with AD, but more comprehensive with IPD. An initial reduced tool was developed through consensus involving 13 advisors, featuring 11 AD items across four domains, and 12 IPD items across eight domains. The tool was iteratively refined throughout piloting and validation. All studies with known integrity issues were accurately identified during validation. The final tool includes seven AD domains with 13 items and eight IPD domains with 18 items. The quality of evidence informing healthcare relies on trustworthy data. We describe the development of a tool to enable researchers, editors, and others to detect integrity issues using IPD. Detailed instructions for its application are published as a complementary manuscript in this issue.</p>\u0000 </section>\u0000 </div>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"940-949"},"PeriodicalIF":5.0,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A re-analysis of about 60,000 sparse data meta-analyses suggests that using an adequate method for pooling matters 对大约 60,000 项稀疏数据荟萃分析的重新分析表明,使用适当的方法进行汇总非常重要。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-08-13 DOI: 10.1002/jrsm.1748
Maxi Schulz, Malte Kramer, Oliver Kuss, Tim Mathes

In sparse data meta-analyses (with few trials or zero events), conventional methods may distort results. Although better-performing one-stage methods have become available in recent years, their implementation remains limited in practice. This study examines the impact of using conventional methods compared to one-stage models by re-analysing meta-analyses from the Cochrane Database of Systematic Reviews in scenarios with zero event trials and few trials. For each scenario, we computed one-stage methods (Generalised linear mixed model [GLMM], Beta-binomial model [BBM], Bayesian binomial-normal hierarchical model using a weakly informative prior [BNHM-WIP]) and compared them with conventional methods (Peto-Odds-ratio [PETO], DerSimonian-Laird method [DL] for zero event trials; DL, Paule-Mandel [PM], Restricted maximum likelihood [REML] method for few trials). While all methods showed similar treatment effect estimates, substantial variability in statistical precision emerged. Conventional methods generally resulted in smaller confidence intervals (CIs) compared to one-stage models in the zero event situation. In the few trials scenario, the CI lengths were widest for the BBM on average and significance often changed compared to the PM and REML, despite the relatively wide CIs of the latter. In agreement with simulations and guidelines for meta-analyses with zero event trials, our results suggest that one-stage models are preferable. The best model can be either selected based on the data situation or, using a method that can be used in various situations. In the few trial situation, using BBM and additionally PM or REML for sensitivity analyses appears reasonable when conservative results are desired. Overall, our results encourage careful method selection.

在稀疏数据荟萃分析(试验数量少或事件为零)中,传统方法可能会扭曲结果。虽然近年来出现了性能更好的单阶段方法,但在实践中的应用仍然有限。本研究通过重新分析科克伦系统综述数据库中的荟萃分析,在零事件试验和少量试验的情况下,检验了使用传统方法与单阶段模型相比所产生的影响。对于每种情况,我们都计算了单阶段方法(广义线性混合模型[GLMM]、贝塔-二叉模型[BBM]、使用弱信息先验的贝叶斯二叉-正态分层模型[BNHM-WIP]),并将其与传统方法(零事件试验的Poto-Odds-ratio[PETO]、DerSimonian-Laird方法[DL];少数试验的DL、Paule-Mandel[PM]、限制最大似然法[REML])进行了比较。虽然所有方法都显示出相似的治疗效果估计值,但在统计精度方面出现了很大的差异。在零事件情况下,传统方法的置信区间(CI)通常小于单阶段模型。在试验次数较少的情况下,BBM 的置信区间平均最宽,尽管 PM 和 REML 的置信区间相对较宽,但与 PM 和 REML 相比,其显著性经常发生变化。我们的结果表明,与模拟结果和零事件试验荟萃分析指南一致,单阶段模型更可取。既可以根据数据情况选择最佳模型,也可以使用一种适用于各种情况的方法。在试验次数较少的情况下,如果希望得到保守的结果,使用 BBM 和 PM 或 REML 进行敏感性分析似乎是合理的。总之,我们的结果鼓励人们谨慎选择方法。
{"title":"A re-analysis of about 60,000 sparse data meta-analyses suggests that using an adequate method for pooling matters","authors":"Maxi Schulz,&nbsp;Malte Kramer,&nbsp;Oliver Kuss,&nbsp;Tim Mathes","doi":"10.1002/jrsm.1748","DOIUrl":"10.1002/jrsm.1748","url":null,"abstract":"<p>In sparse data meta-analyses (with few trials or zero events), conventional methods may distort results. Although better-performing one-stage methods have become available in recent years, their implementation remains limited in practice. This study examines the impact of using conventional methods compared to one-stage models by re-analysing meta-analyses from the Cochrane Database of Systematic Reviews in scenarios with zero event trials and few trials. For each scenario, we computed one-stage methods (Generalised linear mixed model [GLMM], Beta-binomial model [BBM], Bayesian binomial-normal hierarchical model using a weakly informative prior [BNHM-WIP]) and compared them with conventional methods (Peto-Odds-ratio [PETO], DerSimonian-Laird method [DL] for zero event trials; DL, Paule-Mandel [PM], Restricted maximum likelihood [REML] method for few trials). While all methods showed similar treatment effect estimates, substantial variability in statistical precision emerged. Conventional methods generally resulted in smaller confidence intervals (CIs) compared to one-stage models in the zero event situation. In the few trials scenario, the CI lengths were widest for the BBM on average and significance often changed compared to the PM and REML, despite the relatively wide CIs of the latter. In agreement with simulations and guidelines for meta-analyses with zero event trials, our results suggest that one-stage models are preferable. The best model can be either selected based on the data situation or, using a method that can be used in various situations. In the few trial situation, using BBM and additionally PM or REML for sensitivity analyses appears reasonable when conservative results are desired. Overall, our results encourage careful method selection.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"978-987"},"PeriodicalIF":5.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1748","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checking the inventory: Illustrating different methods for individual participant data meta-analytic structural equation modeling 检查清单:说明个体参与者数据元分析结构方程模型的不同方法。
IF 5 2区 生物学 Q1 MATHEMATICAL & COMPUTATIONAL BIOLOGY Pub Date : 2024-08-13 DOI: 10.1002/jrsm.1735
Lennert J. Groot, Kees-Jan Kan, Suzanne Jak

Researchers may have at their disposal the raw data of the studies they wish to meta-analyze. The goal of this study is to identify, illustrate, and compare a range of possible analysis options for researchers to whom raw data are available, wanting to fit a structural equation model (SEM) to these data. This study illustrates techniques that directly analyze the raw data, such as multilevel and multigroup SEM, and techniques based on summary statistics, such as correlation-based meta-analytical structural equation modeling (MASEM), discussing differences in procedures, capabilities, and outcomes. This is done by analyzing a previously published collection of datasets using open source software. A path model reflecting the theory of planned behavior is fitted to these datasets using different techniques involving SEM. Apart from differences in handling of missing data, the ability to include study-level moderators, and conceptualization of heterogeneity, results show differences in parameter estimates and standard errors across methods. Further research is needed to properly formulate guidelines for applied researchers looking to conduct individual participant data MASEM.

研究人员可能掌握着他们希望进行元分析的研究的原始数据。本研究的目的是为希望对原始数据进行结构方程模型(SEM)拟合的研究人员确定、说明和比较一系列可能的分析方案。本研究阐述了直接分析原始数据的技术(如多层次和多组 SEM)和基于汇总统计的技术(如基于相关性的元分析结构方程模型 (MASEM)),讨论了程序、能力和结果方面的差异。这是通过使用开放源码软件分析以前发表的数据集来实现的。使用涉及 SEM 的不同技术,将反映计划行为理论的路径模型与这些数据集进行拟合。除了在处理缺失数据、纳入研究层面调节因素的能力以及异质性概念化方面存在差异外,结果还显示出不同方法在参数估计和标准误差方面的差异。需要进一步开展研究,为希望进行个体参与者数据 MASEM 的应用研究人员制定适当的指导原则。
{"title":"Checking the inventory: Illustrating different methods for individual participant data meta-analytic structural equation modeling","authors":"Lennert J. Groot,&nbsp;Kees-Jan Kan,&nbsp;Suzanne Jak","doi":"10.1002/jrsm.1735","DOIUrl":"10.1002/jrsm.1735","url":null,"abstract":"<p>Researchers may have at their disposal the raw data of the studies they wish to meta-analyze. The goal of this study is to identify, illustrate, and compare a range of possible analysis options for researchers to whom raw data are available, wanting to fit a structural equation model (SEM) to these data. This study illustrates techniques that directly analyze the raw data, such as multilevel and multigroup SEM, and techniques based on summary statistics, such as correlation-based meta-analytical structural equation modeling (MASEM), discussing differences in procedures, capabilities, and outcomes. This is done by analyzing a previously published collection of datasets using open source software. A path model reflecting the theory of planned behavior is fitted to these datasets using different techniques involving SEM. Apart from differences in handling of missing data, the ability to include study-level moderators, and conceptualization of heterogeneity, results show differences in parameter estimates and standard errors across methods. Further research is needed to properly formulate guidelines for applied researchers looking to conduct individual participant data MASEM.</p>","PeriodicalId":226,"journal":{"name":"Research Synthesis Methods","volume":"15 6","pages":"872-895"},"PeriodicalIF":5.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jrsm.1735","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Research Synthesis Methods
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1